Startups
A & B (HK) Company Limited
Wan Chai, Hong Kong
A & B (HK) Company Limited is a privately controlled Hong Kong healthcare and life-science investment company. Acticor’s regulator-approved2021 registration document identifies A&B Venture as a family-office investment vehicle led by Huaizheng Peng. The2019 SEC joint filing confirms that HongKong A&B is wholly owned by A&B BrotherLimited, a distinct BritishVirginIslands company wholly owned by LamKong. It is associated with ChinaMedicalSystem through shared ultimate leadership/control, but it is not CMSMedicalVentureInvestment(HK) or a wholly owned CMSoperating subsidiary. Separate legal buyers retain separate investments; Lam’s control of companies is not evidence of his direct personal check. OfficialGLEIF record549300DB8X2RW1QBWG65 supplies exact legal name, HongKong registry64274051 and UnitA,11/F,ChungPontCommercialBuilding,300HennessyRoad,WanChai address. Entity status is reportedACTIVE, while the LEI registration isLAPSED and last updatedAugust2024; this is not fresh confirmation of every current corporate role. The2019 SEC ScheduleA names LamKong as director and HuaizhengPeng as chief executive, independently consistent with Acticor’s2021 description. Those two published subsidiary leadership affiliations are recorded historically; current CMSparent roles on their full existing biographies remain separate. Their authentic CMS-published individual portraits are reused unchanged. No independently authenticated A&B logo, dedicated website or complete current subsidiary staff directory was located, and no CMSlogo is substituted merely because executives are shared. A&B invested corporate working capital in international product-focused life-science companies. In2019 it paid approximatelyGBP4M for Midatech shares and warrants, separately from CMSHK’s approximatelyGBP4M subscription; licensing royalties, unexercisedwarrants and indirectparentownership are not extra cash. Actual Acticor2018SeriesB participation is confirmed by issuer and statutory document, with subscribing individual ticket unpublished. Its agreement was signedJuly31,2018 alongside separateCMSlicensing/equity agreements; that signing date is not invented as exact publicannouncement or completedcashclosing. The available profile discloses no pooledexternalLPfund closings. Historical financial holdings are not assertions of current portfolio status, successful clinical trials or approved stroke therapy; Acticor entered judicialliquidation inJanuary2025.
Team
 Huaizheng PengChief Executive Officer (historical, confirmed2019–2021) |
 Lam KongDirector (historical, confirmed2019) |
